Sorry, we do not have enough data to show an influence graph for this author.
- Full text PDF available (1)
Journals and Conferences
A 70-year-old man developed severe periorbital edema secondary to imatinib mesylate (Gleevec; Novartis Pharmaceuticals Corp, East Hanover, NJ). Imatinib mesylate is a tyrosine kinase inhibitor with a… (More)